The aminobisphosphonate pamidronate controls influenza pathogenesis by expanding a γδ T cell population in humanized mice by Lam, KT et al.
Title
The aminobisphosphonate pamidronate controls influenza
pathogenesis by expanding a γδ T cell population in
humanized mice
Author(s) Tu, W; Zheng, J; Liu, Y; Sia, SF; Liu, M; Qin, G; Ng, IHY; Xiang, Z;Lam, KT; Peiris, JSM; Lau, YL
Citation Journal Of Experimental Medicine, 2011, v. 208 n. 7, p. 1511-1522
Issued Date 2011
URL http://hdl.handle.net/10722/139524
Rights Creative Commons: Attribution 3.0 Hong Kong License
Article
The Rockefeller University Press $30.00
J. Exp. Med. Vol. 208 No. 7 1511-1522
www.jem.org/cgi/doi/10.1084/jem.20110226
1511
Influenza is an acute respiratory virus infection 
associated with significant morbidity and mor-
tality that continues to threaten global public 
health (Guan et al., 2004; Palese, 2004; Tumpey 
et al., 2005; Dawood et al., 2009; Fraser et al., 
2009; Garten et al., 2009). Both innate and 
adaptive immune systems play critical roles in 
protecting against influenza A viruses, and di-
rect manipulation of host immunity may help 
protect individuals against these viruses (Peiris 
et al., 2009). Inactivated vaccines against seasonal 
influenza viruses are less effective for a novel 
pandemic strain, e.g., pandemic H1N1 virus 
(Hancock et al., 2009), although they may pro-
vide partial cross-protection (Medina et al., 2010; 
Tu et al., 2010). The commercially available anti-
viral agents, the adamantanes and neuramini-
dase inhibitors, target specific viral proteins, 
blocking virus uncoating and inhibiting virus 
release from infected cells, respectively. Viral 
mutation allows influenza viruses to evade the 
action of these antiviral drugs, leading to the 
emergence of antiviral resistance (Lackenby et al., 
2008; Dharan et al., 2009; Layne et al., 2009; 
Moscona, 2009). The development of alterna-
tive strategies to contain virus infection by 
boosting innate immunity has obvious advan-
tages for the treatment of influenza without the 
risk of encouraging antiviral resistance. One 
way to enhance innate immunity is to stimulate 
NK cell activity, but our recent studies demon-
strated that influenza virus can use a novel strategy 
to evade NK cell immunity by directly killing 
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There are few antiviral drugs for treating influenza, and the emergence of antiviral 
resistance has further limited the available therapeutic options. Furthermore, antivirals 
are not invariably effective in severe influenza, such as that caused by H5N1 viruses. 
Thus, there is an urgent need to develop alternative therapeutic strategies. Here, we 
show that human V9V2 T cells expanded by the aminobisphosphonate pamidronate 
(PAM) kill influenza virus–infected cells and inhibit viral replication in vitro. In  
Rag2/c/ immunodeficient mice reconstituted with human peripheral mononuclear 
cells (huPBMCs), PAM reduces disease severity and mortality caused by human seasonal 
H1N1 and avian H5N1 influenza virus, and controls the lung inflammation and viral 
replication. PAM has no such effects in influenza virus–infected Rag2/c/ mice 
reconstituted with V9V2 T cell–depleted huPBMCs. Our study provides proof- 
of-concept of a novel therapeutic strategy for treating influenza by targeting the host 
rather than the virus, thereby reducing the opportunity for the emergence of drug-
resistant viruses. As PAM has been commonly used to treat osteoporosis and Paget’s 
disease, this new application of an old drug potentially offers a safe and readily avail-
able option for treating influenza.
© 2011 Tu et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months it 
is available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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RESULTS
Cytotoxic activity of V9V2 T cells against influenza  
virus in vitro
We recently demonstrated that IPP-expanded V9V2 T cells 
could kill human seasonal influenza H1N1/A/Hong Kong/ 
54/98 (human H1N1) and avian influenza H9N2 and H5N1 
virus–infected, monocyte-derived macrophages (MDMs; Qin 
et al., 2009). To determine whether PAM-expanded V9V2 
T cells have similar effects on virus-infected cells, we exam-
ined their cytolytic activities during the co-culture of PAM-
expanded V9V2 T cells with influenza H1N1/A/PR/8/34 
(PR/8) virus–infected, autologous MDMs. PAM selectively 
expanded V9V2 T cells in vitro (Fig. S1). Similar to in our 
previous study (Qin et al., 2009), V9V2 T cells did not show 
any cytolytic activity against mock-infected MDMs (not de-
picted), but these cells displayed potent cytotoxicity against 
PR/8 H1N1 virus–infected MDMs (Fig. 1 A). V9V2 T cells 
significantly inhibited PR/8 H1N1 virus replication in MDMs 
(Fig. 1 A). In addition, PAM-expanded V9V2 T cells also 
displayed similar cytolytic activities against other influenza virus 
strains, such as H3N2, B, and H5N1 viruses (Fig. S2).
Using neutralizing antibodies for NKG2D and FasL, we 
found that blockades of NKG2D and FasL significantly inhib-
ited the cytolytic activities of V9V2 T cells against PR/8 
virus–infected MDMs (Fig. 1 B). In contrast, there was no signif-
icant change on their cytolytic activity against H1N1-infected 
NK cells and inhibiting NK cell cytotoxicity (Mao et al., 
2009, 2010). We therefore looked for an alternative way of 
augmenting innate immunity.
Another cell type that shares the characteristics of NK 
cells and antigen-presenting cells, playing a critical role in 
innate and adaptive immune responses to infectious agents and 
tumors, is -T cells (Carding and Egan, 2002; Brandes et al., 
2005; Poccia et al., 2005a; Born et al., 2006; Konigshofer and 
Chien, 2006; Eberl and Moser, 2009; Bonneville et al. 2010). 
These cells constitute only 1–5% of T lymphocytes in blood 
and peripheral organs of adult humans and other animals 
(Carding and Egan, 2002; Shen et al., 2002; Poccia et al., 
2005a). In humans, the majority of peripheral blood and lym-
phoid organ -T cells are V9V2 T cells, a major “innate-
like” peripheral T cell subset (Carding and Egan, 2002; Beetz 
et al., 2008).
V9V2 T cells are specifically activated in an HLA- 
unrestricted manner by small nonpeptidic phosphoantigens, 
which are metabolites of isoprenoid biosynthesis pathways 
(Beetz et al., 2008). Isopentenyl pyrophosphate (IPP), an inter-
mediate produced through the mevalonate pathway, was 
found to selectively activate and expand human V9V2 T cells 
in vitro and in vivo (Bonneville and Scotet, 2006; Puan et al., 
2007; Qin et al., 2009). Pharmacological compounds, such as 
the aminobisphosphonates pamidronate (PAM) and zoledro-
nate, which are commonly used for the treatment of osteo-
porosis and Paget’s disease, can induce intracellular accumulation 
of IPP, leading to activation and expansion of human V9V2 
T cells ( Bonneville and Scotet, 2006; Bonneville et al., 2010; 
Urban et al., 2010).
Phosphoantigen-expanded V9V2 T cells were shown 
to have antiviral activity (Poccia et al., 2005a; Agrati et al., 
2006; Poccia et al., 2006). Recently, we demonstrated that 
IPP-expanded V9V2 T cells have potent cytotoxic activity 
against human and avian influenza virus–infected cells (Qin 
et al., 2009), but it is still not known whether PAM-expanded 
V9V2 T cells have similar effects on virus-infected cells. 
We wished to investigate the role of these cells in combating 
influenza virus infection in vivo; however, it was not possible 
to use the conventional mouse or ferret model for these 
studies because murine T cells do not express a homologue of 
the V9V2-TCR (Sicard et al., 2005; Bonneville and Scotet, 
2006; Born et al., 2006), and whether V9V2 T cells exist 
in ferret remains unknown. Studies on nonhuman primates 
are constrained by high cost, limited availability, and lack of 
genetically inbred strains suitable for adoptive cell trans-
plantation (Pearson et al., 2008). In this study, we success-
fully established a humanized mouse model using C57BL/ 
10SgAiRag2/c/ (Rag2/c/) mice, with human 
peripheral blood mononuclear cells (huPBMCs). We dem-
onstrated that PAM effectively controlled human and avian 
influenza virus infections and protected mice from death 
by boosting V9V2 T cell immunity. Our study suggests a 
novel strategy for treatment of seasonal, zoonotic, and pan-
demic influenza by using PAM to enhance host V9V2 
T cell immunity.
Figure 1. Cytotoxicity of PAM-expanded V9V2 T cells against 
virus-infected MDMs. (A) MDMs were infected with PR/8 virus at an 
MOI of 2, and then cultured alone (vMDMs alone) or with purified PAM-
expanded V9V2 T cells at a ratio of 1:10 for 6 h. The percentages of 
dead MDMs among target cells (CD3 population), identified as 
CD3EthD2+ for four different experiments are shown. To determine the 
viral copy, PR/8 virus–infected MDMs were cultured alone or with purified 
PAM-expanded V9V2 T cells for 48 h. Total RNA was extracted from 
both cells and supernatant, and viral matrix gene copies were quantified, 
followed by reverse transcription. The results were shown as virus gene 
copies per 105 MDMs for four different experiments. *, P < 0.05. (B) PAM-
expanded V9V2 T cells were co-cultured with PR/8 virus–infected 
MDMs at a ratio of 10:1 for 6 h. The perforin inhibitor CMA, granzyme B 
inactivator Bcl-2, anti-NKG2D (aNKG2D), anti-TRAIL (aTRAIL), anti-FasL 
(aFasL) blocking antibodies, or their relevant isotype controls, were used. 
The cytotoxicity was analyzed by flow cytometry as the percentage of 
EthD-2+ cells in the CD3 population and calculated as the percentage  
of inhibition relative to those without any treatment. The data shown  
as mean ± SEM are representative of four independent experiments.  
*, P < 0.05 as compared with their relevant isotype control. mIgG1,  
mouse IgG1; mIgG2b, mouse IgG2b; gIgG, goat IgG.
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CD4/CD8 ratio was reversed (Table S1). A booster vaccina-
tion of tetanus toxoid (TT) in these mice induced human 
T and B cell proliferation, TT-specific IFN- secretion in 
human CD4 and CD8 T cells, and serum anti-TT–specific 
human antibody in vivo (Fig. 2 C). Therefore, these chimeric 
Rag2/c/ mice with functional human T and B cells, 
including a similar percentage of V9+V2+ T cells, after 4 wk 
of huPBMC transplantation are used for following experi-
ments and referred to as “humanized” mice.
Antiviral activity of human V9V2 T cells against 
influenza virus infection in vivo
Wild-type, Rag2/c/, and humanized mice were in-
fected with human seasonal influenza human H1N1 virus 
intranasally (i.n.). As this human H1N1 virus is not a mouse-
adapted strain, it does not cause obvious disease in wild-type 
and Rag2/c/ mice (Fig. 3 A and Fig. S4). However, 
it did induce mild disease in mice reconstituted with huPBMCs, 
with evidence of 5–10% weight loss from day 6 after infec-
tion (Fig. 3 B). Mice reconstituted with V9V2 T cell– 
depleted huPBMCs (Fig. S5) showed comparable weight 
loss (Fig. 3 B).
We used adoptive transfer of human V9V2 T cells to 
investigate their antiviral activity in vivo. Highly purified 
(>97%) PAM-expanded V9V2 T cells (106 cells/mouse) 
were adoptively transferred into influenza PR/8 virus–infected 
humanized mice i.v. at day 2, 4, and 6 after infection. Conse-
quently, the frequency of V9V2 T cells in peripheral blood 
lymphocytes in humanized mice increased to a peak level at 
day 5, and then gradually reduced to a basal 
level at day 15 after infection (Table S2). Com-
pared with PBS-treated mice, mice receiving 
PAM-expanded V9V2 T cells showed 
reduced weight loss and less virus replica-
tion in the lungs (Fig. 3, C and D). Impor-
tantly, more survived (Fig. 3 E). These results 
MDMs after TRAIL blocking antibody treatment (Fig. 1 B). 
To further confirm the involvement of cytolytic granule re-
lease in the killing of virus-infected MDMs by V9V2 
T cells, the perforin-specific inhibitor concanamycin A (CMA) 
and the granzyme B inactivator Bcl-2 were used. As shown in 
Fig. 1 B, the cytolytic activities of V9V2 T cells against 
PR/8 virus–infected MDMs were significantly abrogated after 
CMA treatment or Bcl-2 treatment (Fig. 1 B). These results 
indicate that the cytotoxicity of V9V2 T cells is dependent 
on NKG2D activation, and mediated by Fas–FasL and perforin–
granzyme B pathways.
Generation of humanized mice in Rag2/c/ 
immunodeficient mice
To determine the role of human V9V2 T cells in influenza 
A infection in vivo, we reconstituted Rag2/c/ mice 
with human peripheral mononuclear cells (huPBMCs). Human 
lymphocytes had stably engrafted in Rag2/c/ mice by 
4 wk after transplantation, and this stable engraftment was 
maintained for up to 60 wk (Fig. S3). On day 28 after trans-
plantation, 80 and 30% of nucleated cells in the peripheral 
blood were human CD45+ cells and CD3+ T cells, respec-
tively (Fig. 2 A). The lymphocyte population comprised 
CD3+ T cells (69.7%), CD4+ T cells (29.1%), CD8+ T cells 
(37.3%), CD19+ B cells (6.5%), CD56+ NK cells (22.7%), 
V9+V2+ T cells (2.9%), CD25highCD4+ T cells (2.0%), and 
others (1.1%; Fig. 2 B). The percentages of the various human 
lymphocyte populations in mouse peripheral blood were com-
parable to that in huPBMCs before transplantation except the 
Figure 2. Human lymphocyte engraftment and 
functional human T and B cell development in 
huPBMC-transplanted Rag2/c/ mice. (A) The 
percentage of human CD45+ cells and CD3+ T cells in 
peripheral blood nucleated cells in mice (n = 5) at 
indicated time after transplantation. (B) The percent-
age of human lymphocyte subsets in peripheral blood 
lymphocytes in mice (n = 5) at day 28 after trans-
plantation. The data are representative of four inde-
pendent experiments. (C) A booster of TT vaccine (↓) 
was given at day 14 after priming in humanized mice 
4 wk after huPBMC transplantation. The percentages 
of CD4+ T, CD8+ T, CD19+ B cells and IFN-–producing 
cells in CD4+ and CD8+ T cells from peripheral blood 
nucleated cells, and the levels of serum TT-specific 
antibodies at indicated times after the first dose of  
TT vaccination, are shown (n = 6). The data shown  
as mean ± SEM are representative of two indepen-
dent experiments.
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mice, the mice were injected with PAM (10 mg/kg body 
weight) i.p. (Wang et al., 2001). A significant increase in 
human V9V2 T cells was seen in peripheral blood, spleen, 
and liver, but not in lung (Fig. 4, A and B). Importantly, con-
sistent with its effect in humans (Kunzmann et al., 1999), 
PAM expanded only V9V2 T cells, with no such effect on 
other cells, such as CD4, CD8, B, or NK cells (Fig. 4 C). In 
addition, in the absence of influenza infection, there were no 
significant weight changes in PAM-treated Rag2/c/ or 
humanized mice, compared with their controls (Fig. 4 D). 
These results indicated that PAM can selectively expand 
V9V2 T cells in humanized mice, but by itself has no effect 
on weight in mice.
PAM reduces influenza disease severity and mortality
We next investigated whether PAM could control influenza 
infection and disease in humanized mice by expanding V9V2 
T cells in vivo. Humanized mice were infected with PR/8 
virus i.n. and injected with PAM or PBS i.p from day 3 after 
infection. As observed in adoptive transfer experiments (Fig. 3), 
treatment with PAM significantly decreased weight loss and 
mortality in humanized mice (Fig. 5 A). In contrast, PAM had 
no effect in PR/8 virus–infected Rag2/c/ mice, which 
do not have V9V2 T cells (Fig. 5 B).
In humanized mice infected with human seasonal H1N1, 
PAM treatment that began on day 3 after infection com-
pletely prevented weight loss (Fig. 5 C). As human seasonal 
H1N1 virus infection does not kill mice, the effect of PAM 
indicated that PAM-expanded V9V2 T cells can help con-
trol influenza infection in vivo.
Humanized mice contain human NK cells, -T, and 
B cells (Fig. 2 A). Because V9V2 T cells can enhance NK cell 
activity and mediate adaptive immune responses (Brandes et al., 
2005, 2009; Maniar et al., 2010), the antiviral activity of adop-
tively transferred V9V2 T cells may be associated with 
NK cells and adaptive immunity. To exclude this possibility, we 
transferred highly purified (>97%) V9V2 T cells into PR/8 
virus–infected Rag2/c/ mice, which lack both human 
and murine T, B, and NK cells. As in humanized mice, the fre-
quency of V9V2 T cells in peripheral blood lymphocytes in 
Rag2/c/ mice increased to a peak level at day 5, and 
then gradually reduced to a basal level at day 15 after infection 
(Table S2). Mice with adoptively transferred PAM-expanded 
V9V2 T cells also had significantly reduced weight loss and 
mortality, and reduced virus replication in the lung, compared 
with PBS-treated mice (Fig. 3, F–H). These data demonstrated 
that PAM-expanded V9V2 T cells by themselves can effec-
tively control influenza infection in vivo.
PAM selectively expands human V9V2 T cells  
in humanized mice
Consistent with previous studies that PAM could selectively 
expand V9V2 T cells in humans (Kunzmann et al., 1999; 
Das et al., 2001), we also found that PAM specifically expanded 
V9V2 T cells, but not non-V9V2  T cells, in vitro 
(Fig. S1). To determine whether this occurs in humanized 
Figure 3. Antiviral activity of human 
V9V2 T cells against influenza in vivo. 
(A) The body weight changes in wild-type and 
Rag2/c/ mice after infection with  
human H1N1 virus or mock (PBS) i.n. (n = 6 
per group). (B) The body weight changes in 
humanized mice and V9V2 T cell–depleted 
humanized mice (n = 6 per group) after infec-
tion with human H1N1 virus i.n. As the con-
trol, humanized mice (n = 6) were treated 
with PBS (Mock). (C–E) After adoptive transfer 
of in vitro PAM-expanded V9V2 T cells or 
PBS i.v. at day 2, 4, and 6 after infection, the 
body weight changes (n = 8 per group; C), 
lung viral titers (n = 4 per group; D) and sur-
vival (n = 8 per group; E) in PR/8 virus– 
infected humanized mice were measured at 
indicated time after infection. (F–H) After 
adoptive transfer of in vitro PAM-expanded 
V9V2 T cells or PBS i.v. at day 2, 4, and 6 
after infection, the body weight changes  
(n = 8 per group; F), lung viral titers (n = 4 per 
group; G), and survival (n = 8 per group; H) in 
PR/8 virus–infected Rag2/c/ mice were 
measured at indicated time of after infection. 
The data are representative of two indepen-
dent experiments. *, P < 0.05.
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replication of human seasonal H1N1 virus in the lung from 
day 6 onwards (Fig. 6). PAM treatment similarly reduced virus 
titers in the lung of humanized mice infected with avian 
H5N1 or PR/8 by day 10 after infection (Fig. 6). These results 
indicated that PAM treatment leads to the control of virus 
replication in the lung.
PAM prevents inflammation in infected lung
The lungs of humanized mice infected with human seasonal 
H1N1 and avian H5N1 viruses differed in levels of human 
and/or murine proinflammatory cytokines and chemokines, 
such as IL-6, IL-10, TNF, MCP-1, IP-10, IL-8, or RANTES 
(Fig. 7, A and B; and Fig. S7). Consistent with the findings in 
our previous in vitro studies in primary human cells (Cheung 
et al., 2002), avian H5N1 virus induced higher levels of 
human IL-6, TNF, and IP-10 and murine IL-6 and RANTES 
in the lungs of humanized mice compared with H1N1 virus–
infected mice (Fig. 7, A and B; and Fig. S7). PAM treatment 
significantly reduced levels of human IL-10, TNF, and MCP-1 
(Fig. 7 A) and murine MCP-1 in the lungs of human H1N1 
virus–infected humanized mice at day 10 after infection (Fig. S7). 
Similarly, PAM significantly decreased levels of human IL-6, 
IL-10, TNF, IL-8, IP-10, and MCP-1 (Fig. 7 B) and murine 
IL-6, TNF, and RANTES (Fig. S7) in the lungs of avian 
H5N1 virus–infected humanized mice on day 10 after infec-
tion. Furthermore, there were significantly fewer inflammatory 
human lymphocyte (i.e., CD3) infiltrates and less pathology 
in the lungs of human H1N1 or avian H5N1 virus–infected, 
PAM-treated humanized mice on day 6, 10, and 14 after in-
fection, compared with those in PBS-treated mice that were 
infected with the same viruses (Fig. 7, C and D; and Fig. S8). 
Collectively, these results demonstrated that PAM can attenu-
ate the lung inflammation and pathology induced by these 
viruses, possibly via reduction of viral replication.
on mortality could not be investigated. Whereas no V9V2 
T cells were seen in lungs of PAM-treated uninfected human-
ized mice (Fig. 4 B), the accumulation of these cells in the 
lungs of H1N1 virus–infected humanized mice treated with 
PAM on day 6, 10, and 14 after infection was significantly higher 
than those in PBS-treated mice (Fig. 5 D and Fig. S6). These 
results indicated that in vivo PAM-expanded V9V2 T cells 
can move to infected lungs to exert their antiviral activity.
Importantly, treatment with PAM from day 1 after infec-
tion significantly reduced weight loss and mortality caused by 
avian influenza H5N1/A/Hong Kong/486/97 (avian H5N1) 
virus (Fig. 5 E). Significantly more V9V2 T cells accumu-
lated in avian H5N1 virus–infected lung after treatment with 
PAM than after treatment with PBS (Fig. 5 F and Fig. S6), in-
dicating that PAM-expanded V9V2 T cells can also migrate 
to infected lungs to exert their antiviral activity after avian 
H5N1 infection. As Rag2/c/ mice have no V9V2 
T cells, PAM treatment had no beneficial effect in these 
mice after avian H5N1 infection (Fig. 5 G). These observa-
tions exclude the possibility that PAM has direct antiviral 
activity. Without PAM treatment, H5N1 disease progressed 
faster in nonhumanized Rag2/c/ than in humanized 
Rag2/c/ mice (Fig. 5 E vs. Fig. 5 G), suggesting that 
reconstituted huPBMCs may provide some protection dur-
ing the early stage of infection.
Collectively, these results demonstrated that PAM can 
effectively reduce influenza disease severity and mortality 
caused by human H1N1, PR/8, and avian H5N1 viruses.
PAM inhibits influenza virus replication in lung
In humanized mice, influenza virus replicated effectively in 
the lung, and the viral titers of human H1N1 and avian H5N1 
viruses peaked by day 6 and 10 after infection, respectively 
(Fig. 6). Importantly, PAM treatment significantly suppressed 
Figure 4. PAM selectively expands  
human V9V2 T cells in humanized mice. 
(A) The percentage (mean ± SEM) of V9V2  
T cells in peripheral blood lymphocytes in 
humanized mice (n = 4) after 1 dose of PAM 
(10 mg/kg body weight) via i.p injection.  
(B) Accumulation of V9V2 T cells (brown) in 
different tissues at day 2 after 1 dose of PAM 
or PBS. Representative immunohistochemical 
sections from spleen, liver, lung, and intestine 
in uninfected humanized mice stained with 
an anti–human V2 mAb (7B6). Bar, 100 µm. 
(C) Representative data for the percentages of 
V9V2 T cells, CD3+ T, CD4+ T, CD8+ T, CD19+ B, 
and CD56+ NK cells in the peripheral blood 
lymphocytes at day 2 after 1 dose of PAM or 
PBS in uninfected humanized mice (n = 4 per 
group). (D) Body weight changes of human-
ized (n = 5 per group) or Rag2/c/ mice 
(n = 5 per group) after PAM or PBS treatment 
on day 0, 2, 4, and 6. The data are representa-
tive of two independent experiments.
1516 Human  T cells control influenza infection | Tu et al.
humanized mice with V9V2 T cell–depleted huPBMCs 
(Fig. 8). These results demonstrated that the antiviral effect of 
PAM against influenza virus is mainly mediated by a V9V2 
T cell–dependent mechanism.
DISCUSSION
In this study, we have used humanized mice to demonstrate 
that PAM treatment can effectively control influenza virus–
induced disease and that this beneficial effect is mediated by 
boosting human V9V2 T cell immunity. Humanized mice 
are a widely used, powerful, and cost-effective animal model 
for the study of human innate and adaptive immunity to in-
fectious diseases (Ohashi et al., 2000; 
Feuerer et al., 2001; Stoddart et al., 
2001; Traggiai et al., 2004; Jiang et al., 
2008; Pearson et al., 2008). For ex-
ample, chimeric human PBMC-SCID 
mice have been used to study the anti-
bacterial and antitumor effects of human 
V9V2 T cells (Wang et al., 2001; 
Kabelitz et al., 2004; Beck et al., 
2010). The humanized mice established 
here contain functional human T and 
B cells, including a similar percentage 
of V9V2 T cells in peripheral blood 
as seen in humans (Fig. 2 and Table S1). 
Most importantly, we found that influ-
enza viruses could efficiently replicate 
and cause pathology in these mice with 
PAM cannot control influenza diseases in humanized mice 
without V9V2 T cells
To further determine whether antiviral role of PAM against 
influenza virus is mediated by V9V2 T cells in humanized 
mice, humanized mice reconstituted with V9V2 T cell–
depleted huPBMCs (Fig. S5) were used. Mice reconstituted 
with whole huPBMCs or V9V2 T cell–depleted huPBMCs 
were infected with PR/8 virus i.n. and injected with PAM or 
PBS i.p. from day 3 after infection. As shown in Fig. 8, treat-
ment with PAM significantly decreased weight loss and mor-
tality in humanized mice with whole huPBMCs (Fig. 8). In 
contrast, PAM had no such effects in PR/8 virus–infected 
Figure 5. PAM reduces influenza disease 
severity and mortality. (A and B) Mice were 
infected with PR/8 virus and treated with PAM 
or PBS on day 3, 5, 7, and 9 after infection. The 
body weight change and survival in virus-
infected humanized mice (n = 6 per group; A), 
and Rag2/c/ mice (n = 6 per group; B) 
are shown. (C and D) Humanized mice were 
infected with human H1N1 virus and treated 
with PAM or PBS on day 3, 5, 7, and 9 after 
infection. The body weight changes and sur-
vival (C; n = 6 per group), and representative 
immunohistochemical staining for V9V2  
T cells (brown) in the lungs (D) at the indicated 
time after PAM or PBS treatment are shown. 
(E–G) Mice were infected with avian H5N1 
virus and treated with PAM or PBS on day 1, 3, 
5, 7, and 9 after infection. The body weight 
changes and survival (E; n = 12 per group) and 
representative immunohistochemical staining 
for V9V2 T cells (brown) in the lungs (F) at 
indicated time after PAM or PBS treatment are 
shown. The body weight changes and survival 
in avian H5N1 virus–infected Rag2/c/ 
mice (n = 5 per group; G) are also shown. The 
data are representative of two to three inde-
pendent experiments. Bars, 100 µm.
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that IPP-expanded V9V2 T cells can efficiently kill human 
seasonal H1N1- and avian influenza virus H9N2- and H5N1-
infected MDMs, and inhibit virus replications in vitro (Qin 
et al., 2009). In this study, we further showed that PAM- 
expanded V9V2 T cells have a similar antiviral activity against 
influenza PR/8 H1N1 virus (Fig. 1) and other strains, such as 
H3N2, B, and H5N1 viruses (Fig. S2). Importantly, by the use 
of adoptive transfer of in vitro–expanded V9V2 T cells into 
influenza virus–infected immunodeficient Rag2/c/ 
and humanized mice, here we demonstrate for the first time 
that V9V2 T cells can directly inhibit viral replication and 
control influenza disease in vivo (Fig. 3).
Consistent with previous reports about aminobisphos-
phonates in human and nonhuman primates (Das et al., 2001; 
Kunzmann et al., 1999; Sicard et al., 2005), we report that 
PAM can selectively expand V9V2 T cells in humanized 
mice (Fig. 4). Furthermore, we demonstrate that PAM can 
inhibit viral replication, attenuate lung inflammation, and 
control pathology and disease caused by influenza through 
selective activation and expansion of V9V2 T cells in vivo. 
To the best of our knowledge, this is the first demonstration 
of the therapeutic effect of PAM on influenza infections.
V9V2 T cells can mediate elimination of virus-infected 
cells or tumor cells by cytolytic and noncytolytic antiviral 
mechanisms (Bukowski et al., 1994; Battistini et al., 2005; 
Bonneville and Fournié, 2005; Born et al., 2007). Here, we 
found that PAM-expanded V9V2 T cells can recognize and 
efficiently kill influenza PR/8 H1N1 virus–infected cells, and 
thus contribute to virus clearance in vitro (Fig. 1). The cyto-
toxicity of V9V2 T cells against influenza virus–infected 
cells is dependent on NKG2D activation and is mediated by 
the Fas–FasL and perforin–granzyme 
B pathways (Fig. 1). Phosphoantigen-
expanded V9V2 T cells also produce 
large amounts of antiviral cytokines, 
infiltration of inflammatory lymphocytes, the induction of 
proinflammatory cytokines and chemokines in the lung, 
weight loss, and sometimes death (Figs. 5–7). These findings 
indicate that the humanized mice established here are suitable 
for the study of human V9V2 T cell immune responses to 
influenza viruses.
-T cells play critical roles in the defense against infec-
tious pathogens and in tumors (Bukowski et al., 1994; Sciammas 
and Bluestone, 1999; Battistini et al., 2005; Poccia et al., 2005a; 
Scotet et al., 2005). In vitro studies have demonstrated broad 
antiviral activities of human V9V2 T cells against human 
immunodeficiency virus, hepatitis B virus, herpes simplex 
virus, vaccinia virus, human cytomegalovirus and SARS 
coronavirus (Kabelitz et al., 2004; Poccia et al., 2006; Poccia 
et al., 2005a; Sicard et al., 2005). Previously, we had demonstrated 
Figure 6. PAM inhibits influenza virus replication in lung. Human-
ized mice were infected with human H1N1 (n = 5 per group), avian H5N1 
(n = 5 per group), or PR/8 (n = 4 per group) viruses, and treated with PAM 
or PBS as indicated in the legend of Fig. 5. The virus titers in the super-
natants of homogenized lung tissue were determined at the indicated times 
after infection. *, P < 0.05. The data shown as mean ± SEM are represen-
tative of two to three independent experiments.
Figure 7. PAM prevents inflammation in 
infected lung. Humanized mice were in-
fected with human H1N1 (n = 4 per group; A), 
or avian H5N1 (n = 4 per group; B) viruses, 
and treated with PAM or PBS as indicated in 
the legend of Fig. 5. The levels of human pro-
inflammatory cytokines and chemokines in 
the supernatants of homogenized lung tissue 
were determined at the indicated times after 
infection (A and B). The data are shown as 
mean ± SEM. *, P < 0.05. (C and D) Histo-
pathologic changes in mouse lung tissues 
collected at indicated times after infection are 
shown. Representative histological sections of 
the lung tissues from human H1N1 (C) and 
avian H5N1 (D) virus–infected humanized  
mice after PAM or PBS treatment as indicated 
in the legend of Fig. 5 were stained with  
hematoxylin and eosin. Bars, 100 µm.  
The data are representative of three indepen-
dent experiments.
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huPBMCs, whereas PAM could significantly prevent the 
weight loss and death in the mice reconstituted with whole 
huPBMCs (Fig. 8). Therefore, our data unequivocally demon-
strated that the antiviral role of PAM against influenza virus is 
mainly mediated by human V9V2 T cells.
In contrast to our original expectation that the absence of 
V9V2 T cells in humanized mice may allow more severe 
disease to develop after influenza infection than seen in mice 
reconstituted with whole huPBMCs, here we found that 
mice reconstituted with either whole huPBMCs or V9V2 
T cell–depleted huPBMCs showed similar disease severity 
(Fig. 3 B). This is probably because the effector functions of 
V9V2 T cells are dependent on their numbers and the de-
gree of activation (Bonneville and Fournié, 2005; Bonneville 
and Scotet, 2006; Bonneville et al., 2010) and the humanized 
mice contain only a few V9V2 T cells (Fig. 2 and 4B). Our 
in vitro results showed that influenza virus alone could not 
expand V9V2 T cells and only partially activated these cells. 
It was only in the presence of PAM that V9V2 T cells are 
fully activated and expanded in number and to express suffi-
cient perforin and granzyme B to protect against influenza 
infection (Fig. S9).
As observed in humans (Beigel et al., 2005; Cheung et al., 
2002), different strains of influenza virus cause varying disease 
severity in humanized mice. Compared with human seasonal 
H1N1 virus, avian H5N1 virus induced more severe illness, 
pulmonary pathology, and even death in humanized mice 
(Fig. 5; Fig. 7, C and D; Fig. S8). Avian H5N1 virus led to 
higher viral load and induced higher levels of proinflamma-
tory cytokines and chemokines such as IL-6, TNF, and IP-10 
in the lungs (Fig. 6 and 7). It is not clear whether the pro-
inflammatory cytokine induction is simply a reflection of the 
enhanced H5N1 viral replication or whether it contributes to 
immunopathology itself. In vitro studies in primary human 
cells have shown that, compared with seasonal influenza viruses, 
H5N1 virus intrinsically causes enhanced cytokine expres-
sion (Cheung et al., 2002; Chan et al., 2005). In the human-
ized mice, all the T, B, and NK cells derive from human origin, 
whereas its lung epithelial cells derive exclusively from mouse 
origin. Thus, influenza infection in these mice is associated 
with the expression of cytokines/chemokines of human and 
mouse origin (Fig. 7 and Fig. S7). Because human cytokines 
may or may not have physiological activity in mouse lung epi-
thelium, this is not a perfect model of influenza pathogenesis. 
However, this humanized mouse model provides a relevant 
and valuable model for the study of the role of the innate-like 
V9V2 T cells in influenza infections because the effector 
functions of V9V2 T cells do not require conventional 
antigen presentation in the context of the MHC (Bonneville 
and Scotet, 2006; Urban et al., 2010). We used this model to 
demonstrate that expansion and activation of V9V2 T cells 
by PAM effectively control influenza virus disease.
Notably, human seasonal H1N1 virus could not efficiently 
infect wild-type or Rag2/c/ mice, but it did success-
fully infect humanized mice as indicated by the virus replication 
in the lung and the significant body weight loss (Fig. 3 and 6; 
such as IFN- (Poccia et al., 2005b). Consistent with a previ-
ous report that avian influenza H5N1 is resistant to the anti-
viral effects of IFN- (Seo et al., 2002), we also found that 
IFN- secreted from phosphoantigen-expanded V9V2 
T cells only suppressed human H1N1 virus replication, but 
did not affect avian H5N1 viral replication in vitro (unpub-
lished data). Here, we further found that PAM-expanded 
V9V2 T cells in vivo migrated to influenza virus–infected 
lungs of humanized mice and contributed to the control of 
virus replication and disease (Fig. 5 and 6; and Fig. S6). There-
fore, we speculate that during influenza virus infections in 
these humanized mice, human V9V2 T cells activated and 
expanded by PAM may clear human H1N1 viruses by di-
rectly killing the virus-infected cells and secreting IFN- to 
inhibit virus replication, but for H5N1 infection, the virus 
clearance may be mainly dependent on their direct killing. 
The lack of a beneficial effect of PAM in influenza virus–infected 
Rag2/c/ mice excludes the possibility that this drug 
has a direct antiviral effect on influenza virus.
Our in vitro study has indicated that PAM largely ex-
panded V9V2 T cells, but did not expand non-V9V2  
T cells. The number of V9V2 T cells was 63.9 times higher 
than that of non-V9V2  T cells after 9 d of PAM stimu-
lation (Fig. S1). Although non-V9V2  T cells could be 
also activated by PAM, the frequencies of CD69+, perforin+, 
and granzyme B+ cells in non-V9V2  T cells were sig-
nificantly lower than that in V9V2 T cells (Fig. S1). Indeed, 
our adoptive transfer experiments in Rag2/c/ mice 
(Fig. 3, F–H) have demonstrated that PAM-expanded V9V2 
T cells by themselves effectively controlled influenza infec-
tion in vivo, as Rag2/c/ mice lack both human and 
murine T, B, and NK cells. Importantly, we also found that PAM 
could not prevent weight loss and death caused by influenza 
virus in the mice reconstituted with V9V2 T cell–depleted 
Figure 8. PAM cannot control influenza diseases in humanized 
mice without V9V2 T cells. V9V2 T cell–depleted huPBMCs were 
obtained after double depletions of V2 T cells by positive selection with 
magnetic microbeads. Rag2/c/ mice were transplanted with  
30 × 106 of huPBMCs or V9V2 T cell-depleted huPBMCs i.p. from the same 
healthy human donor. In contrast with the mice reconstituted with whole 
huPBMCs, there were no or very few human V9V2 T cells in the mice 
reconstituted with V9V2 T cell–depleted huPBMCs (Fig. S5). Humanized 
mice reconstituted with whole huPBMCs (PBMC) or V9V2 T cell–depleted 
huPBMCs (PBMC--T) were infected with PR/8 virus, and treated with 
PAM or PBS on day 3, 5, 7 and 9 after infection. The body weight change 
and survival in virus-infected humanized mice (n = 4 per group) are 
shown. The data are representative of two independent experiments.
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after depletion of V2 T cells by magnetic microbeads (Miltenyi Biotec). 4–5-
wk-old male or female Rag2/c/ mice were treated with liposomes 
(VU Medisch Centrum, Amsterdam, the Netherlands) 1 d before transplanta-
tion. The sublethally irradiated mice were transplanted i.p. with 30 × 106 
huPBMCs or V9V2 T cell–depleted huPBMCs. In general, huPBMCs 
from 1 buffy coat were used for generation of 8–10 humanized mice. After 
transplantation, graft-versus-host disease symptoms such as weight loss, tem-
perature changes, and diarrhea were monitored daily. The immune reconsti-
tution of humanized mice was examined at indicated times. All manipulations 
were performed in compliance with the approval of the Institutional Review 
Board of the University of Hong Kong/Hospital Authority Hong Kong West 
Cluster and the guidelines for the use of experimental animals by the Com-
mittee on the Use of Live Animals in Teaching and Research, Hong Kong.
Viruses, infections, and treatment of virus-infected humanized mice. 
Human influenza virus H1N1 (A/Hong Kong/54/98), mouse-adapted 
influenza H1N1 (A/PR/8/34), and avian H5N1 (A/Hong Kong/486/97) 
were used. All the viruses were cultured in Madin-Darby canine kidney cells, 
as described previously (Qin et al., 2009; Tu et al., 2010). The virus titer was 
determined by daily observation of cytopathic effect in cells infected with 
serial dilutions of virus stock; median tissue culture infective dose (TCID50) 
was calculated according to the Reed-Muench formula. For in vitro experi-
ments, day 14–differentiated MDMs were infected by influenza virus at a 
multiplicity of infection (MOI) of 2. After 1 h of viral adsorption, the cells 
were washed by PBS to remove un-adsorbed virus.
Humanized mice were separated into mock, PBS-treated, and drug-treated 
groups and matched according to sex, age, and the source of huPBMCs. 
4 wk after transplantation of huPBMCs, Rag2/c/ and established human-
ized mice were infected i.n. with human influenza H1N1 virus (25 µl, 
108.4TCID50), PR/8 virus (25 µl, 104TCID50), or avian influenza H5N1 (25 µl, 
1 × LD50) under anesthesia. For human H1N1 and PR/8 virus infection, a 
human equivalent dose of PAM (10 mg/kg body weight; Pamisol; Hospira 
Australia Pty Led) or an equivalent volume of PBS was injected i.p. on days 
3, 5, 7, and 9 after virus infection. For avian H5N1 infection, PAM (10 mg/kg 
body weight) or an equivalent volume of PBS was injected i.p. on days 1, 3, 
5, 7, and 9 after virus infection. Survival was monitored, and the infected 
mice were weighed daily: mice with >25% weight loss were sacrificed and 
counted as dying.
Cytotoxic assay. V9V2 T cells (Effector, E) were co-cultured with PR/8 
virus–infected MDMs (Target, T) at an E/T ratio of 10:1 for 6 h. Afterward, 
nonadherent cells were harvested directly. Adherent cells were detached with 
0.25% trypsin-EDTA. All the adherent and nonadherent cells were stained 
with anti-CD3 to identify V9V2 T cells and ethidium homodimer-2 
(EthD-2) to identify dead cells (King, 2000). The cytotoxicity of V9V2 
T cells against virus-infected MDMs was assessed by flow cytometry as the 
percentage of EthD-2+ cells in the CD3 population as we did before (Qin 
et al., 2009).
Quantification of fluA viral copies by RT-PCR. MDMs (105) were in-
fected by PR/8 virus at an MOI of 2. 1 h later, un-adsorbed virus was washed 
away carefully and the MDMs were cultured alone or with 106 of V9V2 
T cells for 48 h. Then the cells and supernatant were harvested and total RNA 
was extracted by TRIzol LS reagent according to the manufacturer’s instruc-
tions (Invitrogen). The cDNA was synthesized with oligo(dT)12-18 primer 
and Superscript II reverse transcription (Invitrogen). Viral matrix gene copies 
were quantified on the basis of a SYBR green fluorescence signal after PCR 
(forward primer, 5-CTTCTAACCGAGGTCGAAACG-3; reverse primer, 
5-GGCATTTTGGACAAAGCGTCTA-3) by ABI PRISM 7700 Se-
quence Detection System (Applied Biosystems; Qin et al., 2009). Results 
were expressed as the number of target gene copies per 105 MDMs.
Blocking assay. V9V2 T cells (E) were co-cultured with PR/8 virus–
infected MDMs (T) at an E/T ratio of 10: 1 for 6 h. The neutralization anti-
bodies anti-NKG2D (10 µg/ml; 1D11; BD), anti-FasL (10 µg/ml; 100419; 
and Fig. S4). Importantly, as for avian H5N1 virus, human 
seasonal H1N1 virus could infect both human and mouse 
cells in the lung in humanized mice (Fig. S10), suggesting that 
the process of humanization may alter the lung tissue tropism 
for influenza virus in mice. This needs to be investigated by 
examining the expression of the H1N1 virus receptor in the 
respiratory tract and lung in humanized mice.
The significance of targeting V9V2 T cells rather than 
the influenza virus itself lies in their innatelike effector func-
tions that allow them to exhibit their antiviral activities 
rapidly, regardless of virus subtype and the emergence of drug-
resistant strains. The use of a human equivalent dose of PAM 
can effectively control influenza diseases in humanized mice 
suggesting it is feasible to translate to human clinical trials. 
Several protocols based on the in vivo activation of V9V2 
T cells with phosphoantigens or aminobisphophonates are in 
development for the treatment of certain tumors and bacterial 
infections (Bonneville and Scotet, 2006; Caccamo et al., 2008; 
Dieli et al., 2008; Huang et al., 2009; Bonneville et al., 2010).
In summary, our study demonstrates that PAM controls 
influenza infection in humanized mice by inhibition of virus 
replication and associated attenuation of inflammation in the 
lungs through boosting the human V9V2 T cells, and that 
this beneficial effect is active against viruses of varying sub-
types and virulence. Our findings confirm proof of principle 
for a novel therapeutic approach—using PAM to boost human 
V9V2 T cell immunity against seasonal, zoonotic, and pan-
demic influenza viruses. These studies now deserve to be ex-
tended to human clinical trials. As PAM is commonly used 
clinically for the treatment of osteoporosis and Paget’s disease, 
this new application of an old drug potentially offers a safe and 
readily available option either alone or in combination with 
conventional antiviral drugs for the treatment of influenza, 
especially for combating pandemic or drug-resistant viruses.
MATERIALS AND METHODS
Generation of PAM-expanded V9V2 T cells and MDMs. PBMCs 
were isolated from buffy coats of health donors from Hong Kong Red Cross 
by Ficoll-Hypaque (Pharmacia) gradient centrifugation as previously de-
scribed (Tu et al., 2006). The research protocol was approved by the Institu-
tional Review Board of the University of Hong Kong/Hospital Authority 
Hong Kong West Cluster. PBMCs were cultured in 10% FBS RPMI-1640 
medium with 9 µg/ml of PAM. Recombinant human IL-2 (Invitrogen) was 
added to a final concentration of 500 IU/ml every 3 d from day 3. After 14-d 
culture, V9V2 T cells were purified by negative selection with TCR /+ 
T cell isolation kit according to the manufacturer’s instruction (Miltenyi Bio-
tec). Human MDMs were generated from mononuclear cells as previously 
described (Zhou et al., 2006). In brief, adherent monocytes were seeded in 
96-well flat-bottomed plates at 105 cells/well or in 24-well plates at 5 × 105 
cells/well. Then they were refed by RPMI-1640 supplemented with 5% 
autologous serum and allowed to differentiate to macrophages for 14 d. The 
purity of monocytes, as determined by flow cytometry with anti-CD14 
monoclonal antibody, was consistently >90%.
Generation of humanized mice. Rag2/c/ mice were purchased 
from Taconic and maintained in the Laboratory Animal Unit, the University 
of Hong Kong. To establish humanized mice models, huPBMCs were iso-
lated from buffy coat preparations of blood from healthy donors from the 
Hong Kong Red Cross. V9V2 T cell–depleted huPBMCs were obtained 
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Online supplemental material. Fig. S1 demonstrates that PAM selec-
tively expands human V9V2 T cells in vitro. Fig. S2 indicates that PAM-
expanded V9V2 T cells display cytolytic activities against influenza H3N2, 
B, and H5N1 viruses. Fig. S3 shows the generation of humanized mice in 
Rag2/c/ mice with huPBMCs. Fig. S4 demonstrates human H1N1 virus 
cannot infect wild-type and Rag2/c/ mice. Fig. S5 shows the genera-
tion of humanized mice with V9V2 T cell–depleted huPBMCs. Fig. S6 
shows the numbers of V9V2 T cells in the lungs of virus–infected human-
ized mice after treatment with PAM. Fig. S7 shows that effects of PAM on 
murine proinflammatory cytokines and chemokines in virus-infected lung 
in humanized mice. Fig. S8 shows the pathology score and infiltrated human 
CD3 in the lungs of human H1N1 or avian H5N1 virus–infected, PAM-
treated humanized mice after infection. Fig. S9 demonstrates that PAM en-
hances influenza virus–stimulated V9V2 T cells activation and expression 
of perforin and granzyme B. Fig. S10 shows that human H1N1 and avian 
H5N1 viruses infect both human and murine cells in the lung of humanized 
mice. Table S1 shows the percentages of peripheral blood lymphocyte sub-
sets before and after transplantation in humanized mice. Table S2 shows the 
frequencies of V9V2 T cells in peripheral blood lymphocytes in mice after 
adoptive transfer of V9V2 T cells. Online supplemental material is available 
at http://www.jem.org/cgi/content/full/jem.20110226/DC1.
We thank M. Bonneville and E. Scotet for providing anti–human TCR2  
(7B6) antibody for our immunohistochemistry assay and W.H.S. Wong  
for statistical analyses.
This work was supported in part by the Area of Excellence program on 
Influenza supported by the University Grants Committee of the Hong Kong SAR, 
China (Project No AoE/M-12/06; J.S.M. Peiris, Y.-L. Lau, and W. Tu); the Research 
Fund for the Control of Infectious Diseases, Hong Kong SAR government 
(07060482; W. Tu); the General Research Fund, Research Grants Council of Hong 
Kong (HKU 777108M, HKU777407, and HKU768108; W. Tu and Y.-L. Lau).
Author contributions: W. Tu conceived and designed the study, designed all the 
experiments, analyzed data, and wrote the paper; J. Zheng designed and performed 
parts of experiments, and analyzed data; Y. Liu, S.F. Sia, M. Liu, G. Qin, I.H.Y. Ng, 
Z. Xiang, and K.T. Lam performed parts of experiments; J.S.M. Peiris and Y.-L. Lau 
conceived and planned the study and co-wrote the paper.
The authors declare no competing financial interests.
Submitted: 31 January 2011
Accepted: 31 May 2011
REFERENCES
Agrati, C., T. Alonzi, R. De Santis, C. Castilletti, I. Abbate, M.R. Capobianchi, 
G. D’Offizi, F. Siepi, G.M. Fimia, M. Tripodi, and F. Poccia. 2006. 
Activation of Vgamma9Vdelta2 T cells by non-peptidic antigens induces 
the inhibition of subgenomic HCV replication. Int. Immunol. 18:11–18. 
doi:10.1093/intimm/dxh337
Battistini, L., N. Caccamo, G. Borsellino, S. Meraviglia, D.F. Angelini, F. Dieli, 
M.T. Cencioni, and A. Salerno. 2005. Homing and memory patterns 
of human gammadelta T cells in physiopathological situations. Microbes 
Infect. 7:510–517. doi:10.1016/j.micinf.2004.12.008
Beck, B.H., H.G. Kim, H. Kim, S. Samuel, Z. Liu, R. Shrestha, H. Haines, 
K. Zinn, and R.D. Lopez. 2010. Adoptively transferred ex vivo expanded 
gammadelta-T cells mediate in vivo antitumor activity in preclinical mouse 
models of breast cancer. Breast Cancer Res. Treat. 122:135–144. doi:10 
.1007/s10549-009-0527-6
Beetz, S., D. Wesch, L. Marischen, S. Welte, H.H. Oberg, and D. Kabelitz. 2008. 
Innate immune functions of human gammadelta T cells. Immunobiology. 
213:173–182. doi:10.1016/j.imbio.2007.10.006
Beigel, J.H., J. Farrar, A.M. Han, F.G. Hayden, R. Hyer, M.D. de Jong, S. 
Lochindarat, T.K. Nguyen, T.H. Nguyen, T.H. Tran, et al; Writing 
Committee of the World Health Organization (WHO) Consultation on 
Human Influenza A/H5. 2005. Avian influenza A (H5N1) infection in 
humans. N. Engl. J. Med. 353:1374–1385. doi:10.1056/NEJMra052211
Bonneville, M., and J.J. Fournié. 2005. Sensing cell stress and transforma-
tion through Vgamma9Vdelta2 T cell-mediated recognition of the 
R&D Systems), anti-TRAIL (10 µg/ml; RIK-2; R&D Systems), and their 
relevant isotype controls were added in the co-culture for blocking NKG2D-, 
FasL-, and TRAIL-mediated pathways, respectively (Mattarollo et al., 2007). 
For blocking perforin and granzyme B, the perforin inhibitor CMA (1 µg/ml; 
Sigma-Aldrich) and granzyme B inactivator Bcl-2 (1 µg/ml; R&D Systems) 
were used as previously described (Zeine et al., 1998). The cytotoxicities 
were analyzed by flow cytometry as described in cytotoxic assay and calcu-
lated as percentage of inhibition relative to those of control.
Immunization. 4 wk after transplantation of huPBMCs, established hu-
manized mice were primed with 1.5 limits of flocculation (lf) of TT vaccine 
(Adventis-Pasteur) subcutaneously in the inguinal pouch region. A booster 
vaccination of 0.25 lf TT was given in the right hind footpad 2 wk after 
priming. The numbers of human CD4 T cells, CD8 T cells, and CD19 B cells 
in mouse peripheral blood were counted by FACS analysis, and IFN-- 
producing cells in CD4 and CD8 T cells in peripheral blood were analyzed 
by intracellular cytokine staining. The serum TT-specific antibody was 
examined by ELISA.
Flow cytometric analysis. Cells were stained for surface markers with the 
following antibodies: anti-CD3 (HIT3a), anti-TCR9 (B3), anti-TCR2 
(B6; BD), anti-TCR (5A6.E9), and anti-CD14 (TUK4; Invitrogen). For 
intracellular staining, cells were fixed, permeabilized, and then stained with 
anti–IFN-, anti-perforin (Pfp, G9), and anti–granzyme B (GrB, GB11) 
antibodies (BD) or their relevant isotype controls as described previously 
(Tu et al., 2004; Zheng et al., 2009). All samples were acquired on a FACSAria 
(BD) and analyzed by FlowJo software (Tree Star).
ELISA assay. The concentrations of total human IgG or TT-specific IgG in 
the serum of humanized mice were determined by quantitative ELISA set 
(Bethyl Laboratories, Inc.).
Determination of virus titer and inflammatory cytokines and che-
mokines. The lungs from infected humanized mice were harvested at indi-
cated times and homogenized in 2 ml of PBS. After centrifugation at 1,500 g 
for 15 min, the supernatants were collected for determination of virus titer 
and inflammatory cytokines and chemokines. The concentrations of human 
and murine cytokines and chemokines were detected and analyzed with human 
cytokine and chemokine assay kits (Bender MedSystems).
Immunohistochemistry assays of lungs. The lungs, livers, spleens, kidneys, 
and intestines from Rag2/c/ mice or humanized mice were harvested 
at indicated times, fixed with 10% formalin, and maintained in 75% ethanol. 
Sections were prepared according to standard protocols and stained with 
hematoxylin and eosin, or anti–human CD45, anti–human CD3 (Abcam), or 
anti–human TCR2 antibody (clone 7B6; gift from M. Bonneville and E. 
Scotet, Institut National de la Santé et de la Recherche Médicale U892, Paris, 
France), and visualized by HRP-Polymer anti–mouse/rabbit IHC kit (Max-
Vision; China). Histopathologic score and the number of CD3+ and V2+ 
cells in lung tissues was analyzed by two independent observers who were 
blinded to the treatment. The lung tissue sections were screened, and five 
fields for each mouse were selected randomly. Histopathologic score was 
evaluated as previously described (Dybing et al., 2000). The severity was 
graded on a scale of 0 to 3: normal, 0; mild, 1; moderate, 2; severe, 3. The nu-
cleated CD3+ and V2+ cells in each area were counted at ×40 magnification 
and expressed as the number of cells per field (Kuang et al., 2009).
Statistical analyses. Data are means ± SEM. Multiple regression analysis 
was used to test the differences in the body weight changes between PBS and 
V9V2 T cell–treated or PAM-treated groups adjusted for time after infec-
tion. The differences in cell death and viral copy for in vitro experiments, and 
viral titers or concentrations of proinflammatory cytokines/chemokines 
between PBS and V9V2 T cell–treated or PAM-treated groups were ana-
lyzed by unpaired two-tailed Student’s t test. The P value of the difference for 
survival was determined by Kaplan-Meier log-rank test. P < 0.05 was con-
sidered to be significant.
JEM Vol. 208, No. 7 
Article
1521
Fraser, C., C.A. Donnelly, S. Cauchemez, W.P. Hanage, M.D. Van Kerkhove, 
T.D. Hollingsworth, J. Griffin, R.F. Baggaley, H.E. Jenkins, E.J. Lyons, 
et al; WHO Rapid Pandemic Assessment Collaboration. 2009. Pandemic 
potential of a strain of influenza A (H1N1): early findings. Science. 
324:1557–1561. doi:10.1126/science.1176062
Garten, R.J., C.T. Davis, C.A. Russell, B. Shu, S. Lindstrom, A. Balish, W.M. 
Sessions, X. Xu, E. Skepner, V. Deyde, et al. 2009. Antigenic and genetic 
characteristics of swine-origin 2009 A(H1N1) influenza viruses circulat-
ing in humans. Science. 325:197–201. doi:10.1126/science.1176225
Guan, Y., L.L. Poon, C.Y. Cheung, T.M. Ellis, W. Lim, A.S. Lipatov, K.H. Chan, 
K.M. Sturm-Ramirez, C.L. Cheung, Y.H. Leung, et al. 2004. H5N1 in-
fluenza: a protean pandemic threat. Proc. Natl. Acad. Sci. USA. 101:8156–
8161. doi:10.1073/pnas.0402443101
Hancock, K., V. Veguilla, X. Lu, W. Zhong, E.N. Butler, H. Sun, F. Liu, L. 
Dong, J.R. DeVos, P.M. Gargiullo, et al. 2009. Cross-reactive antibody 
responses to the 2009 pandemic H1N1 influenza virus. N. Engl. J. Med. 
361:1945–1952. doi:10.1056/NEJMoa0906453
Huang, D., C.Y. Chen, Z. Ali, L. Shao, L. Shen, H.A. Lockman, R.E. Barnewall, 
C. Sabourin, J. Eestep, A. Reichenberg, et al. 2009. Antigen-specific 
Vgamma2Vdelta2 T effector cells confer homeostatic protection against 
pneumonic plaque lesions. Proc. Natl. Acad. Sci. USA. 106:7553–7558. 
doi:10.1073/pnas.0811250106
Jiang, Q., L. Zhang, R. Wang, J. Jeffrey, M.L. Washburn, D. Brouwer, S. 
Barbour, G.I. Kovalev, D. Unutmaz, and L. Su. 2008. FoxP3+CD4+ 
regulatory T cells play an important role in acute HIV-1 infection in 
humanized Rag2-/-gammaC-/- mice in vivo. Blood. 112:2858–2868. 
doi:10.1182/blood-2008-03-145946
Kabelitz, D., D. Wesch, E. Pitters, and M. Zöller. 2004. Characterization of 
tumor reactivity of human V gamma 9V delta 2 gamma delta T cells in 
vitro and in SCID mice in vivo. J. Immunol. 173:6767–6776.
King, M.A. 2000. Detection of dead cells and measurement of cell killing 
by flow cytometry. J. Immunol. Methods. 243:155–166. doi:10.1016/ 
S0022-1759(00)00232-5
Konigshofer, Y., and Y.H. Chien. 2006. Gammadelta T cells - innate im-
mune lymphocytes? Curr. Opin. Immunol. 18:527–533. doi:10.1016/ 
j.coi.2006.07.008
Kuang, D.M., Q. Zhao, C. Peng, J. Xu, J.P. Zhang, C. Wu, and L. Zheng. 2009. 
Activated monocytes in peritumoral stroma of hepatocellular carcinoma 
foster immune privilege and disease progression through PD-L1. J. Exp. 
Med. 206:1327–1337. doi:10.1084/jem.20082173
Kunzmann, V., E. Bauer, and M. Wilhelm. 1999. Gamma/delta T-cell 
stimulation by pamidronate. N. Engl. J. Med. 340:737–738. doi:10 
.1056/NEJM199903043400914
Lackenby, A., C.I. Thompson, and J. Democratis. 2008. The potential impact 
of neuraminidase inhibitor resistant influenza. Curr. Opin. Infect. Dis. 
21:626–638. doi:10.1097/QCO.0b013e3283199797
Layne, S.P., A.S. Monto, and J.K. Taubenberger. 2009. Pandemic influ-
enza: an inconvenient mutation. Science. 323:1560–1561. doi:10.1126/ 
science.323.5921.1560
Mao, H., W. Tu, G. Qin, H.K. Law, S.F. Sia, P.L. Chan, Y. Liu, K.T. Lam, J. 
Zheng, M. Peiris, and Y.L. Lau. 2009. Influenza virus directly infects 
human natural killer cells and induces cell apoptosis. J. Virol. 83:9215–
9222. doi:10.1128/JVI.00805-09
Mao, H., W. Tu, Y. Liu, G. Qin, J. Zheng, P.L. Chan, K.T. Lam, J.S. Peiris, 
and Y.L. Lau. 2010. Inhibition of human natural killer cell activity 
by influenza virions and hemagglutinin. J. Virol. 84:4148–4157. doi: 
10.1128/JVI.02340-09
Maniar, A., X. Zhang, W. Lin, B.R. Gastman, C.D. Pauza, S.E. Strome, 
and A.I. Chapoval. 2010. Human gammadelta T lymphocytes induce 
robust NK cell-mediated antitumor cytotoxicity through CD137 en-
gagement. Blood. 116:1726-1733.
Mattarollo, S.R., T. Kenna, M. Nieda, and A.J. Nicol. 2007. Chemotherapy 
and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 
T cell cytotoxicity. Cancer Immunol. Immunother. 56:1285–1297. doi:10 
.1007/s00262-007-0279-2
Medina, R.A., B. Manicassamy, S. Stertz, C.W. Seibert, R. Hai, R.B. Belshe, 
S.E. Frey, C.F. Basler, P. Palese, and A. Garcia-Sastre. 2010. Pandemic 
2009 H1N1 vaccine protects against 1918 Spanish influenza virus. Nat. 
Commun. 1:1–6. doi:10.1038/ncomms1026
isoprenoid pathway metabolites. Microbes Infect. 7:503–509. doi:10.1016/ 
j.micinf.2005.03.004
Bonneville, M., and E. Scotet. 2006. Human Vgamma9Vdelta2 T cells: prom-
ising new leads for immunotherapy of infections and tumors. Curr. Opin. 
Immunol. 18:539–546. doi:10.1016/j.coi.2006.07.002
Bonneville, M., R.L. O’Brien, and W.K. Born. 2010. Gammadelta T cell ef-
fector functions: a blend of innate programming and acquired plasticity. 
Nat. Rev. Immunol. 10:467–478. doi:10.1038/nri2781
Born, W.K., C.L. Reardon, and R.L. O’Brien. 2006. The function of gamma-
delta T cells in innate immunity. Curr. Opin. Immunol. 18:31–38. doi:10 
.1016/j.coi.2005.11.007
Born, W.K., N. Jin, M.K. Aydintug, J.M. Wands, J.D. French, C.L. Roark, 
and R.L. O’Brien. 2007. gammadelta T lymphocytes-selectable cells 
within the innate system? J. Clin. Immunol. 27:133–144. doi:10.1007/ 
s10875-007-9077-z
Brandes, M., K. Willimann, and B. Moser. 2005. Professional antigen- 
presentation function by human gammadelta T Cells. Science. 309:264–268. 
doi:10.1126/science.1110267
Brandes, M., K. Willimann, G. Bioley, N. Lévy, M. Eberl, M. Luo, R. Tampé, 
F. Lévy, P. Romero, and B. Moser. 2009. Cross-presenting human gam-
madelta T cells induce robust CD8+ alphabeta T cell responses. Proc. 
Natl. Acad. Sci. USA. 106:2307–2312. doi:10.1073/pnas.0810059106
Bukowski, J.F., C.T. Morita, and M.B. Brenner. 1994. Recognition and de-
struction of virus-infected cells by human gamma delta CTL. J. Immunol. 
153:5133–5140.
Caccamo, N., S. Meraviglia, F. Scarpa, C. La Mendola, D. Santini, C.T. Bonanno, 
G. Misiano, F. Dieli, and A. Salerno. 2008. Aminobisphosphonate- 
activated gammadelta T cells in immunotherapy of cancer: doubts no more. 
Expert Opin. Biol. Ther. 8:875–883. doi:10.1517/14712598.8.7.875
Carding, S.R., and P.J. Egan. 2002. Gammadelta T cells: functional plasticity 
and heterogeneity. Nat. Rev. Immunol. 2:336–345. doi:10.1038/nri797
Chan, M.C., C.Y. Cheung, W.H. Chui, S.W. Tsao, J.M. Nicholls, Y.O. Chan, 
R.W. Chan, H.T. Long, L.L. Poon, Y. Guan, and J.S. Peiris. 2005. Proinflam-
matory cytokine responses induced by influenza A (H5N1) viruses in 
primary human alveolar and bronchial epithelial cells. Respir. Res. 6:135. 
doi:10.1186/1465-9921-6-135
Cheung, C.Y., L.L. Poon, A.S. Lau, W. Luk, Y.L. Lau, K.F. Shortridge, S. 
Gordon, Y. Guan, and J.S. Peiris. 2002. Induction of proinflammatory 
cytokines in human macrophages by influenza A (H5N1) viruses: a 
mechanism for the unusual severity of human disease? Lancet. 360:1831–
1837. doi:10.1016/S0140-6736(02)11772-7
Das, H., L. Wang, A. Kamath, and J.F. Bukowski. 2001. Vgamma2Vdelta2 
T-cell receptor-mediated recognition of aminobisphosphonates. Blood. 
98:1616–1618. doi:10.1182/blood.V98.5.1616
Dawood, F.S., S. Jain, L. Finelli, M.W. Shaw, S. Lindstrom, R.J. Garten, L.V. 
Gubareva, X. Xu, C.B. Bridges, and T.M. Uyeki; Novel Swine-Origin 
Influenza A (H1N1) Virus Investigation Team. 2009. Emergence of a 
novel swine-origin influenza A (H1N1) virus in humans. N. Engl. J. Med. 
360:2605–2615. doi:10.1056/NEJMoa0903810
Dharan, N.J., L.V. Gubareva, J.J. Meyer, M. Okomo-Adhiambo, R.C. 
McClinton, S.A. Marshall, K. St George, S. Epperson, L. Brammer, A.I. 
Klimov, et al; Oseltamivir-Resistance Working Group. 2009. Infections 
with oseltamivir-resistant influenza A(H1N1) virus in the United States. 
JAMA. 301:1034–1041. doi:10.1001/jama.2009.294
Dieli, F., N. Caccamo, and S. Meraviglia. 2008. Advances in immunotherapy 
of castration-resistant prostate cancer: bisphosphonates, phosphoantigens 
and more. Curr. Opin. Investig. Drugs. 9:1089–1094.
Dybing, J.K., S. Schultz-Cherry, D.E. Swayne, D.L. Suarez, and M.L. Perdue. 
2000. Distinct pathogenesis of hong kong-origin H5N1 viruses in mice 
compared to that of other highly pathogenic H5 avian influenza viruses. 
J. Virol. 74:1443–1450. doi:10.1128/JVI.74.3.1443-1450.2000
Eberl, M., and B. Moser. 2009. Monocytes and gammadelta T cells: close 
encounters in microbial infection. Trends Immunol. 30:562–568. doi:10 
.1016/j.it.2009.09.001
Feuerer, M., P. Beckhove, L. Bai, E.F. Solomayer, G. Bastert, I.J. Diel, C. 
Pedain, M. Oberniedermayr, V. Schirrmacher, and V. Umansky. 2001. 
Therapy of human tumors in NOD/SCID mice with patient-derived 
reactivated memory T cells from bone marrow. Nat. Med. 7:452–458. 
doi:10.1038/86523
1522 Human  T cells control influenza infection | Tu et al.
Sicard, H., S. Ingoure, B. Luciani, C. Serraz, J.J. Fournié, M. Bonneville, J. 
Tiollier, and F. Romagné. 2005. In vivo immunomanipulation of 
V gamma 9V delta 2 T cells with a synthetic phosphoantigen in a pre-
clinical nonhuman primate model. J. Immunol. 175:5471–5480.
Stoddart, C.A., T.J. Liegler, F. Mammano, V.D. Linquist-Stepps, M.S. Hayden, 
S.G. Deeks, R.M. Grant, F. Clavel, and J.M. McCune. 2001. Impaired 
replication of protease inhibitor-resistant HIV-1 in human thymus. Nat. 
Med. 7:712–718. doi:10.1038/89090
Traggiai, E., L. Chicha, L. Mazzucchelli, L. Bronz, J.C. Piffaretti, A. 
Lanzavecchia, and M.G. Manz. 2004. Development of a human adaptive 
immune system in cord blood cell-transplanted mice. Science. 304:104–
107. doi:10.1126/science.1093933
Tu, W., S. Chen, M. Sharp, C. Dekker, A.M. Manganello, E.C. Tongson, H.T. 
Maecker, T.H. Holmes, Z. Wang, G. Kemble, et al. 2004. Persistent and 
selective deficiency of CD4+ T cell immunity to cytomegalovirus in 
immunocompetent young children. J. Immunol. 172:3260–3267.
Tu, W., L. Potena, P. Stepick-Biek, L. Liu, K.Y. Dionis, H. Luikart, W.F.  
Fearon, T.H. Holmes, C. Chin, J.P. Cooke, et al. 2006. T-cell immunity 
to subclinical cytomegalovirus infection reduces cardiac allograft disease. 
Circulation. 114:1608–1615. doi:10.1161/CIRCULATIONAHA. 
105.607549
Tu, W., H. Mao, J. Zheng, Y. Liu, S.S. Chiu, G. Qin, P.L. Chan, K.T. Lam, J. 
Guan, L. Zhang, et al. 2010. Cytotoxic T lymphocytes established by 
seasonal human influenza cross-react against 2009 pandemic H1N1 in-
fluenza virus. J. Virol. 84:6527–6535. doi:10.1128/JVI.00519-10
Tumpey, T.M., C.F. Basler, P.V. Aguilar, H. Zeng, A. Solórzano, D.E. 
Swayne, N.J. Cox, J.M. Katz, J.K. Taubenberger, P. Palese, and 
A. García-Sastre. 2005. Characterization of the reconstructed 1918 
Spanish influenza pandemic virus. Science. 310:77–80. doi:10.1126/ 
science.1119392
Urban, E.M., A.I. Chapoval, and C.D. Pauza. 2010. Repertoire development 
and the control of cytotoxic/effector function in human gammadelta 
T cells. Clin. Dev. Immunol. 2010:732893. doi:10.1155/2010/732893
Wang, L., A. Kamath, H. Das, L. Li, and J.F. Bukowski. 2001. Antibacterial 
effect of human V gamma 2V delta 2 T cells in vivo. J. Clin. Invest. 
108:1349–1357.
Zeine, R., R. Pon, U. Ladiwala, J.P. Antel, L.G. Filion, and M.S. Freedman. 
1998. Mechanism of gammadelta T cell-induced human oligodendro-
cyte cytotoxicity: relevance to multiple sclerosis. J. Neuroimmunol. 87:49–
61. doi:10.1016/S0165-5728(98)00047-2
Zheng, J., Y. Liu, G. Qin, P.L. Chan, H. Mao, K.T. Lam, D.B. Lewis, Y.L. 
Lau, and W. Tu. 2009. Efficient induction and expansion of human 
alloantigen-specific CD8 regulatory T cells from naive precursors by 
CD40-activated B cells. J. Immunol. 183:3742–3750. doi:10.4049/ 
jimmunol.0901329
Zhou, J., H.K. Law, C.Y. Cheung, I.H. Ng, J.S. Peiris, and Y.L. Lau. 2006. 
Functional tumor necrosis factor-related apoptosis-inducing ligand 
production by avian influenza virus-infected macrophages. J. Infect. Dis. 
193:945–953. doi:10.1086/500954
Moscona, A. 2009. Global transmission of oseltamivir-resistant influenza. N. 
Engl. J. Med. 360:953–956. doi:10.1056/NEJMp0900648
Ohashi, K., P.L. Marion, H. Nakai, L. Meuse, J.M. Cullen, B.B. Bordier, R. 
Schwall, H.B. Greenberg, J.S. Glenn, and M.A. Kay. 2000. Sustained 
survival of human hepatocytes in mice: A model for in vivo infection 
with human hepatitis B and hepatitis delta viruses. Nat. Med. 6:327–331. 
doi:10.1038/73187
Palese, P. 2004. Influenza: old and new threats. Nat. Med. 10:S82–S87. 
doi:10.1038/nm1141
Pearson, T., D.L. Greiner, and L.D. Shultz. 2008. Humanized SCID mouse 
models for biomedical research. Curr. Top. Microbiol. Immunol. 324:25–51. 
doi:10.1007/978-3-540-75647-7_2
Peiris, J.S., W.W. Tu, and H.L. Yen. 2009. A novel H1N1 virus causes the first 
pandemic of the 21st century. Eur. J. Immunol. 39:2946–2954. doi:10 
.1002/eji.200939911
Poccia, F., C. Agrati, F. Martini, M.R. Capobianchi, M. Wallace, and M. 
Malkovsky. 2005a. Antiviral reactivities of gammadelta T cells. Microbes 
Infect. 7:518–528. doi:10.1016/j.micinf.2004.12.009
Poccia, F., C. Agrati, F. Martini, G. Mejia, M. Wallace, and M. Malkovsky. 
2005b. Vgamma9Vdelta2 T cell-mediated non-cytolytic antiviral mecha-
nisms and their potential for cell-based therapy. Immunol. Lett. 100:14–
20. doi:10.1016/j.imlet.2005.06.025
Poccia, F., C. Agrati, C. Castilletti, L. Bordi, C. Gioia, D. Horejsh, G. Ippolito, 
P.K. Chan, D.S. Hui, J.J. Sung, et al. 2006. Anti-severe acute respiratory 
syndrome coronavirus immune responses: the role played by V gamma 
9V delta 2 T cells. J. Infect. Dis. 193:1244–1249. doi:10.1086/502975
Puan, K.J., C. Jin, H. Wang, G. Sarikonda, A.M. Raker, H.K. Lee, M.I.  
Samuelson, E. Märker-Hermann, L. Pasa-Tolic, E. Nieves, et al. 2007. Prefer-
ential recognition of a microbial metabolite by human Vgamma2Vdelta2 
T cells. Int. Immunol. 19:657–673. doi:10.1093/intimm/dxm031
Qin, G., H. Mao, J. Zheng, S.F. Sia, Y. Liu, P.L. Chan, K.T. Lam, J.S. Peiris, Y.L. 
Lau, and W. Tu. 2009. Phosphoantigen-expanded human gammadelta 
T cells display potent cytotoxicity against monocyte-derived macro-
phages infected with human and avian influenza viruses. J. Infect. Dis. 
200:858–865. doi:10.1086/605413
Sciammas, R., and J.A. Bluestone. 1999. TCRgammadelta cells and viruses. 
Microbes Infect. 1:203–212. doi:10.1016/S1286-4579(99)80035-5
Scotet, E., L.O. Martinez, E. Grant, R. Barbaras, P. Jenö, M. Guiraud, B. 
Monsarrat, X. Saulquin, S. Maillet, J.P. Estève, et al. 2005. Tumor recog-
nition following Vgamma9Vdelta2 T cell receptor interactions with a 
surface F1-ATPase-related structure and apolipoprotein A-I. Immunity. 
22:71–80. doi:10.1016/j.immuni.2004.11.012
Seo, S.H., E. Hoffmann, and R.G. Webster. 2002. Lethal H5N1 influenza 
viruses escape host anti-viral cytokine responses. Nat. Med. 8:950–954. 
doi:10.1038/nm757
Shen, Y., D. Zhou, L. Qiu, X. Lai, M. Simon, L. Shen, Z. Kou, Q. Wang, L. Jiang, 
J. Estep, et al. 2002. Adaptive immune response of Vgamma2Vdelta2+ 
T cells during mycobacterial infections. Science. 295:2255–2258. doi:10 
.1126/science.1068819
